EM2308C "Translating Enzyme Biologics for Mineralization and Autoimmune Disease into the clinic - an Academic Perspective" (IM GR-081123)

Purpose and Overview

This lecture will cover examples of enzyme biologics developed in academia and then translated bench to bedside into the clinic. One example will be an early-stage asset, and a second example a late-stage asset about to begin phase 3 clinical trials. Specifically, enzyme biologics for mineralization autoimmune diseases occurring in the rare disease and general medical population will be discussed, beginning with disease pathophysiology, then the design and optimization of biologics to ameliorate disease progression and severity, and concluding with the use of animal models to validate efficacy.

Target Audience

UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.

Learning Objectives

At the conclusion of this activity, the participant should be able to:

  • Understand the relationship between the development of lupus autoimmunity, loss of tolerance to self-DNA in lupus, and the innate immune system.
  • Understand the phenotype of patients with 'paradoxical mineralization disorder' and identify rare and common mineralization diseases in which paradoxical mineralization occurs.
  • Understand the differing risk and efficacy profiles for small molecule and biologic therapeutic drug development for rare and common disease. 
Course summary
Available credit: 
  • 1.00 AMA
Course opens: 
Course expires: 

Photo: First Last, M.D.Demetrios Braddock, M.D., Ph.D.
Associate Professor of Pathology
Brady Memorial Lab
Yale University School of Medicine

Available Credit

  • 1.00 AMA


Please login or create an account to take this course.

Required Hardware/software

Activities should be run with recent versions of common browsers, including Internet Explorer, Firefox and Google Chrome